by Natalja Genina, Associate professor, University of Copenhagen
The conventional manufacturing methods for pharmaceutical dosage forms have limitations in provision of personalized medicine in regard to patient-tailored dose, surface design, color, etc. Furthermore, the end-users have difficulties in identifying their own medicine. In addition, falsified medicines become more and more sophisticated.
All these limitations may be solved by the fabrication of unique cryptopharmaceuticals, e.g., in the pattern of a Quick Response (QR) code that contains a drug and at the same time securely encapsulates information relevant to different stakeholders. Secured QR pattern helps the authorized parties (e.g., patient, nurse and/or pharmacist) not only to administer the correct medicine, containing the right dose at the correct time, but also to verify the authenticity of the received pharmaceutical product and track-and-trace its supply chain.
Question 1: What drives you?
I find it exciting to work in the pioneering research related to printable medicine.
Question 2: Why should the delegate attend your presentation?
To learn on how the digital and pharmaceutical world can bridge together.
Question 3: What emerging technologies/trends do you see as having the greatest potential in the short and long run?
Digital pharmaceuticals will be in game in the near future.
Question 4: What kind of impact do you expect them to have?
These new cryptopharmaceuticals can pay the way to the safe and effective medicine in the future.
Question 5: What are the barriers that might stand in the way?
Regulatory challenges have to be solved before it becomes the reality
About Natalja Genina
Dr Natalja Genina is an Associate professor at the Department of Pharmacy, University of Copenhagen, Denmark. She is a pharmacist by training, and obtained her PhD from University of Helsinki (Finland). Her postdoctoral studies (ca. 2011-2014) were conducted at Åbo Akademi University (Finland), where she was involved in the Finnish Funding Agency for Innovation TEKES ‘pPOD – printable pharmaceuticals’ project (2011-2014) and ‘VitaPrint’ project (2012-2014).